118 related articles for article (PubMed ID: 11831906)
1. Synthesis and biological activity of the prodrug of class I major histocompatibility peptide GILGFVFTL activated by beta-glucuronidase.
Rawale S; Hrihorczuk LM; Wei WZ; Zemlicka J
J Med Chem; 2002 Feb; 45(4):937-43. PubMed ID: 11831906
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics study of a complex between the human histocompatibility antigen HLA-A2 and the IMP58-66 nonapeptide from influenza virus matrix protein.
Rognan D; Zimmermann N; Jung G; Folkers G
Eur J Biochem; 1992 Aug; 208(1):101-13. PubMed ID: 1511679
[TBL] [Abstract][Full Text] [Related]
3. Duocarmycin-based prodrugs for cancer prodrug monotherapy.
Tietze LF; Schuster HJ; Schmuck K; Schuberth I; Alves F
Bioorg Med Chem; 2008 Jun; 16(12):6312-8. PubMed ID: 18524605
[TBL] [Abstract][Full Text] [Related]
4. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2.
Parker KC; Bednarek MA; Hull LK; Utz U; Cunningham B; Zweerink HJ; Biddison WE; Coligan JE
J Immunol; 1992 Dec; 149(11):3580-7. PubMed ID: 1331239
[TBL] [Abstract][Full Text] [Related]
5. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
Leu YL; Chen CS; Wu YJ; Chern JW
J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological activity of beta-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT.
de Bont DB; Leenders RG; Haisma HJ; van der Meulen-Muileman I; Scheeren HW
Bioorg Med Chem; 1997 Feb; 5(2):405-14. PubMed ID: 9061205
[TBL] [Abstract][Full Text] [Related]
7. Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy.
Houba PH; Leenders RG; Boven E; Scheeren JW; Pinedo HM; Haisma HJ
Biochem Pharmacol; 1996 Aug; 52(3):455-63. PubMed ID: 8687500
[TBL] [Abstract][Full Text] [Related]
8. Tax and M1 peptide/HLA-A2-specific Fabs and T cell receptors recognize nonidentical structural features on peptide/HLA-A2 complexes.
Biddison WE; Turner RV; Gagnon SJ; Lev A; Cohen CJ; Reiter Y
J Immunol; 2003 Sep; 171(6):3064-74. PubMed ID: 12960332
[TBL] [Abstract][Full Text] [Related]
9. A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy.
Compain G; Oumata N; Clarhaut J; Péraudeau E; Renoux B; Galons H; Papot S
Eur J Med Chem; 2018 Oct; 158():1-6. PubMed ID: 30199702
[TBL] [Abstract][Full Text] [Related]
10. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
11. Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex.
Hoffmann TK; Donnenberg VS; Friebe-Hoffmann U; Meyer EM; Rinaldo CR; DeLeo AB; Whiteside TL; Donnenberg AD
Cytometry; 2000 Dec; 41(4):321-8. PubMed ID: 11084618
[TBL] [Abstract][Full Text] [Related]
12. Five viral peptide-HLA-A2 co-crystals. Simultaneous space group determination and X-ray data collection.
Garboczi DN; Madden DR; Wiley DC
J Mol Biol; 1994 Jun; 239(4):581-7. PubMed ID: 7516439
[TBL] [Abstract][Full Text] [Related]
13. Partially modified retro-inverso pseudopeptides as non-natural ligands for the human class I histocompatibility molecule HLA-A2.
Guichard G; Connan F; Graff R; Ostankovitch M; Muller S; Guillet JG; Choppin J; Briand JP
J Med Chem; 1996 May; 39(10):2030-9. PubMed ID: 8642561
[TBL] [Abstract][Full Text] [Related]
14. Prodrug Mono Therapy: synthesis and biological evaluation of an etoposide glucuronide-prodrug.
Schmidt F; Monneret C
Bioorg Med Chem; 2003 May; 11(10):2277-83. PubMed ID: 12713838
[TBL] [Abstract][Full Text] [Related]
15. Ultrasound-directed enzyme-prodrug therapy (UDEPT) using self-immolative doxorubicin derivatives.
Roemhild K; Besse HC; Wang B; Peña Q; Sun Q; Omata D; Ozbakir B; Bos C; Scheeren HW; Storm G; Metselaar JM; Yu H; Knüchel-Clarke R; Kiessling F; Moonen CTW; Deckers R; Shi Y; Lammers T
Theranostics; 2022; 12(10):4791-4801. PubMed ID: 35832083
[No Abstract] [Full Text] [Related]
16. Procedure for preparing peptide-major histocompatibility complex tetramers for direct quantification of antigen-specific cytotoxic T lymphocytes.
He XH; Xu LH; Liu Y
World J Gastroenterol; 2005 Jul; 11(27):4180-7. PubMed ID: 16015686
[TBL] [Abstract][Full Text] [Related]
17. Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells.
Zweerink HJ; Gammon MC; Utz U; Sauma SY; Harrer T; Hawkins JC; Johnson RP; Sirotina A; Hermes JD; Walker BD
J Immunol; 1993 Mar; 150(5):1763-71. PubMed ID: 7679694
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
[TBL] [Abstract][Full Text] [Related]
19. The kinetics of peptide binding to HLA-A2 and the conformation of the peptide-A2 complex can be determined by amino acid side chains on the floor of the peptide binding groove.
Shimojo N; Anderson RW; Mattson DH; Turner RV; Coligan JE; Biddison WE
Int Immunol; 1990; 2(3):193-200. PubMed ID: 2088485
[TBL] [Abstract][Full Text] [Related]
20. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
